MannKind announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insuli…
Oral Insulin
Study Shows AFREZZA Safe and Effective in Controlling Blood Glucose Levels
MannKind Corp. announced the results of a two year study comparing the efficacy and safety of AFREZZA (insulin human [rD…
FDA Requests Additional Information From Mannkind Corp. Regarding AFREZZA
MannKind Corporation announced that it has received a Complete Response letter from the U.S. Food & Drug Administration …
Novo Nordisk Starts Phase 1 Trial With Oral Insulin
Novo Nordisk announced today that it has initiated its first phase 1 clinical trial with an oral insulin analogue (NN195…
Novo Nordisk: Progress Made in Oral Insulin Development
Lars Sorensen, Novo's chief executive, speaking at the Reuters Health Summit, said the company could introduce a oral in…
